(Q35226268)

7 August 2017

1 reference

title

Optimal sequencing in the treatment of recurrent ovarian cancer (English)

1 reference

7 August 2017

1 reference

David Spriggs

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

90

1 reference

7 August 2017

issue

3 Pt 2

1 reference

7 August 2017

page(s)

S39-44

1 reference

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Cancer multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Drug resistance in ovarian cancer - the role of p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Clinical experience with topotecan in relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Phase II study of gemcitabine in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

Weekly topotecan in the management of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900471-2

7 January 2021

10.1016/S0090-8258(03)00471-2

Identifiers

DOI

1 reference

7 August 2017

1 reference